国际肝病:在中国促红细胞生成素的应用如何?
Hepatology Digest: What about in China and the use of erythropoietin?
关于促红细胞生成素- A (EPO - A)应用于创伤患者治疗急性期的现存临床证据仅14篇已发表文献。
The existing evidence on the early use of EPO-A in the acute phase of trauma patients management consists of only 14 publications.
促红细胞生成素是一种造血因子,临床中广泛应用于治疗各种原因造成的贫血。
Erythropoietin, the principal regulator of erythroids progenitor cells, is widely used to treat anemia caused by many diseases.
Because we've learned about that biology we've been able to make erythropoietin outside the body and use it as a drug.
由于我们已经知道了这种生物学机制,因此我们能体外制造促红细胞生成素,并作为药品应用
应用推荐